| Dr John Patrick Mcloughlin, DPM | |
|
830 Oak St, Suite 222e, Brockton, MA 02301-1168 | |
| (508) 586-4444 | |
| (508) 586-4709 |
| Full Name | Dr John Patrick Mcloughlin |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 34 Years |
| Location | 830 Oak St, Brockton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780658427 | NPI | - | NPPES |
| 0357782 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0000X | Podiatrist - Sports Medicine | PD 1969 (Massachusetts) | Primary |
| 213ES0131X | Podiatrist - Foot Surgery | PD 1969 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Good Samaritan Medical Center | Brockton, MA | Hospital |
| Massachusetts General Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
| J W Podiatry Pc | 9133137920 | 3 |
News Archive
OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).
Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.
Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours.
Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?
› Verified 6 days ago
| Provider Name | J W Podiatry Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1629294020 PECOS PAC ID: 9133137920 Enrollment ID: O20060405000529 |
News Archive
OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).
Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.
Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours.
Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?
› Verified 6 days ago
| Provider Name | Steward Medical Group Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).
Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.
Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours.
Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?
› Verified 6 days ago
| Provider Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).
Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.
Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours.
Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Patrick Mcloughlin, DPM 34 Lee St, Boston, MA 02130-3251 Ph: (617) 524-0322 | Dr John Patrick Mcloughlin, DPM 830 Oak St, Suite 222e, Brockton, MA 02301-1168 Ph: (508) 586-4444 |
News Archive
OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).
Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.
Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours.
Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?
› Verified 6 days ago
Marc Scott Spiegel, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 680 Centre St, Brockton, MA 02302 Phone: 508-941-7885 Fax: 508-941-6337 | |
Dr. Francis William Swierupski, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 500 Belmont St, Suite 110, Brockton, MA 02301 Phone: 508-586-0540 Fax: 508-588-0466 | |
Dr. Brian Chester Sperre, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1351 Main St, Brockton, MA 02301 Phone: 508-586-3613 Fax: 508-586-3613 | |
Alan G. Krantz, D.p.m., P.c. Podiatrist Medicare: Medicare Enrolled Practice Location: 400 West St, Brockton, MA 02301 Phone: 508-587-9500 Fax: 508-580-6869 | |
J W Podiatry Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 22 Christy Dr, 5, Brockton, MA 02301 Phone: 508-586-4444 Fax: 508-586-4449 | |
Dr. Alan G Krantz, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 400 West St, Brockton, MA 02301 Phone: 508-587-9500 Fax: 508-580-6869 | |
Francis W Swierupski Dpm Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 500 Belmont St, #110, Brockton, MA 02301 Phone: 508-586-0540 Fax: 508-588-0466 |